Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV.
作者信息
Eke Ahizechukwu C, Mirochnick Mark, Lockman Shahin
机构信息
From the Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, and the Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore (A.C.E.); the Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine (M.M.), the Division of Infectious Diseases, Brigham and Women's Hospital (S.L.), and the Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health (S.L.) - all in Boston; and the Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana (S.L.).
出版信息
N Engl J Med. 2023 Jan 26;388(4):344-356. doi: 10.1056/NEJMra2212877.
Abstract
摘要
相似文献
1
Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV.抗逆转录病毒疗法与艾滋病毒感染者的不良妊娠结局
N Engl J Med. 2023 Jan 26;388(4):344-356. doi: 10.1056/NEJMra2212877.
2
Antiretroviral drug use during pregnancy and risk of premature delivery: is there a connection?孕期使用抗逆转录病毒药物与早产风险：二者有关联吗？
J Infect Dis. 2010 Apr 1;201(7):978-80. doi: 10.1086/651233.
3
Considerations on the potential teratogenic effects of antiretroviral therapy.关于抗逆转录病毒疗法潜在致畸作用的思考。
Intern Emerg Med. 2006;1(3):249-50. doi: 10.1007/BF02934751.
4
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.在接受抗逆转录病毒治疗的 HIV 感染孕妇中，无论是否接触过奈韦拉平，肝毒性风险均增加。
AIDS. 2009 Nov 27;23(18):2425-30. doi: 10.1097/QAD.0b013e32832e34b1.
5
Antiretroviral use during pregnancy for treatment or prophylaxis.妊娠期抗逆转录病毒治疗或预防应用。
Expert Opin Pharmacother. 2011 Aug;12(12):1875-85. doi: 10.1517/14656566.2011.584062. Epub 2011 May 3.
6
Antiretroviral Options and Treatment Decisions During Pregnancy.孕期抗逆转录病毒治疗方案与治疗决策
Paediatr Drugs. 2023 May;25(3):267-282. doi: 10.1007/s40272-023-00559-w. Epub 2023 Feb 2.
7
Immunological and hematological effects of perinatal exposure to antiretroviral drugs in HIV exposed, non infected children.围产期暴露于抗逆转录病毒药物对暴露于HIV但未感染儿童的免疫和血液学影响。
Indian Pediatr. 2013 Jun 8;50(6):565-6. doi: 10.1007/s13312-013-0159-0.
8
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染女性的母体毒性和妊娠并发症：艾滋病临床试验组316研究
Am J Obstet Gynecol. 2004 Feb;190(2):506-16. doi: 10.1016/j.ajog.2003.07.018.
9
Lessons from the 11th conference on retroviruses and opportunistic infections.第十一届逆转录病毒与机会性感染会议的经验教训。
AIDS Read. 2004 Apr;14(4):151-3.
10
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.撒哈拉以南非洲地区用于预防母婴传播艾滋病毒的抗逆转录病毒药物：平衡疗效与婴儿毒性
AIDS. 2008 Nov 12;22(17):2359-69. doi: 10.1097/QAD.0b013e3283189bd7.
引用本文的文献
1
Abortion and its association with antiretroviral therapy among young women living with HIV in northern Uganda: a cross-sectional study.乌干达北部感染艾滋病毒的年轻女性中堕胎及其与抗逆转录病毒疗法的关联：一项横断面研究。
AIDS Res Ther. 2025 Aug 29;22(1):84. doi: 10.1186/s12981-025-00777-x.
2
Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database.多替拉韦的上市后安全性问题：一项基于美国食品药品监督管理局不良事件报告系统数据库的药物警戒研究。
Front Pharmacol. 2025 Jul 30;16:1625601. doi: 10.3389/fphar.2025.1625601. eCollection 2025.
3
Antiretroviral Therapy at Conception Leads to Lower Peripheral CD49a NK Cells and Higher SERPINB2.受孕时接受抗逆转录病毒疗法会导致外周血CD49a自然杀伤细胞数量减少以及丝氨酸蛋白酶抑制剂B2水平升高。
J Immunol Res. 2025 May 21;2025:4771787. doi: 10.1155/jimr/4771787. eCollection 2025.
4
Perinatal outcomes among pregnant women with HIV initiating antiretroviral therapy preconception and antenatally.在孕前和孕期开始抗逆转录病毒治疗的感染艾滋病毒孕妇中的围产期结局。
AIDS. 2025 Apr 1;39(5):584-596. doi: 10.1097/QAD.0000000000004104. Epub 2025 Jan 9.
5
Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV.IMPAACT 2010/VESTED试验中的后续妊娠：感染艾滋病毒女性不良结局发生率高。
J Acquir Immune Defic Syndr. 2024 Oct;97(2):150-155. doi: 10.1097/qai.0000000000003473.
6
Adverse birth outcome research case definitions associated with maternal HIV and antiretroviral drug use in pregnancy: a scoping review.与孕期孕产妇感染艾滋病毒及使用抗逆转录病毒药物相关的不良出生结局研究病例定义：一项范围综述
BMC Pregnancy Childbirth. 2024 Dec 21;24(1):844. doi: 10.1186/s12884-024-06939-5.
7
Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review.多替拉韦/拉米夫定在HIV-1感染孕妇管理中的作用：一项叙述性综述
Infect Dis Ther. 2025 Jan;14(1):59-80. doi: 10.1007/s40121-024-01085-z. Epub 2024 Dec 9.
8
Exposure to the antiretroviral drug dolutegravir impairs structure and neurogenesis in a forebrain organoid model of human embryonic cortical development.在人类胚胎皮质发育的前脑类器官模型中，接触抗逆转录病毒药物多替拉韦会损害结构和神经发生。
Front Mol Neurosci. 2024 Nov 6;17:1459877. doi: 10.3389/fnmol.2024.1459877. eCollection 2024.
9
Care of the Child Perinatally Exposed to Human Immunodeficiency Virus.围产期暴露于人类免疫缺陷病毒的儿童的护理。
Clin Perinatol. 2024 Dec;51(4):881-894. doi: 10.1016/j.clp.2024.08.011.
10
Care of Pregnant Women Living with Human Immunodeficiency Virus.艾滋病病毒感染孕妇的护理。
Clin Perinatol. 2024 Dec;51(4):749-767. doi: 10.1016/j.clp.2024.08.010.
本文引用的文献
1
Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081.孕期起始基于raltegravir 或 efavirenz 的抗逆转录病毒治疗方案对体重变化和围产期结局的影响：NICHD P1081。
J Acquir Immune Defic Syndr. 2022 Dec 1;91(4):403-409. doi: 10.1097/QAI.0000000000003081.
2
Update of Perinatal Human Immunodeficiency Virus Type 1 Transmission in France: Zero Transmission for 5482 Mothers on Continuous Antiretroviral Therapy From Conception and With Undetectable Viral Load at Delivery.法国围产期人类免疫缺陷病毒 1 型传播的更新：5482 名从受孕开始接受连续抗逆转录病毒治疗且分娩时病毒载量不可检测的母亲无传播。
Clin Infect Dis. 2023 Feb 8;76(3):e590-e598. doi: 10.1093/cid/ciac703.
3
Altered adipose tissue macrophage populations in people with HIV on integrase inhibitor-containing antiretroviral therapy.接受含整合酶抑制剂的抗逆转录病毒治疗的 HIV 感染者中脂肪组织巨噬细胞群体的改变。
AIDS. 2022 Sep 1;36(11):1493-1500. doi: 10.1097/QAD.0000000000003278. Epub 2022 Jul 8.
4
Neurodevelopmental outcomes of HIV/antiretroviral drug perinatally exposed uninfected children aged 3-6 years.HIV/抗逆转录病毒药物围产期暴露而未感染的 3-6 岁儿童的神经发育结局。
AIDS. 2022 Sep 1;36(11):1533-1543. doi: 10.1097/QAD.0000000000003290. Epub 2022 Jun 22.
5
Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis.评估接受抗逆转录病毒疗法治疗的艾滋病毒感染者体重增加情况的证据综合分析——一项系统文献综述和网状荟萃分析。
EClinicalMedicine. 2022 May 12;48:101412. doi: 10.1016/j.eclinm.2022.101412. eCollection 2022 Jun.
6
Timing of Antiretroviral Therapy: Initiation and Birth Outcomes Among Pregnant Women With Human Immunodeficiency Virus in Tanzania.抗逆转录病毒疗法的时机：坦桑尼亚艾滋病毒感染孕妇的起始治疗时间和母婴结局。
J Infect Dis. 2022 Sep 4;226(4):687-695. doi: 10.1093/infdis/jiac224.
7
Adverse perinatal outcomes associated with timing of initiation of antiretroviral therapy: Systematic review and meta-analysis.与抗逆转录病毒治疗开始时间相关的不良围产期结局：系统评价和荟萃分析。
HIV Med. 2023 Feb;24(2):111-129. doi: 10.1111/hiv.13326. Epub 2022 Jun 6.
8
Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis.与基于蛋白酶抑制剂的抗逆转录病毒疗法相关的围产期不良结局：一项针对感染HIV的孕妇的系统评价和荟萃分析。
EClinicalMedicine. 2022 Apr 6;46:101368. doi: 10.1016/j.eclinm.2022.101368. eCollection 2022 Apr.
9
Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis.抗逆转录病毒疗法时代艾滋病毒暴露但未感染儿童的早期神经发育：系统评价和荟萃分析。
Lancet Child Adolesc Health. 2022 Jun;6(6):393-408. doi: 10.1016/S2352-4642(22)00071-2. Epub 2022 Apr 26.
Zotero 插件